Finally, as there is currently a lack of targeted therapy in thyroid cancer, especially for non-iodine-avid lesions [26], and as an inhibitor of PACE4 has already been developed and tested in cellulo for various cancer types [30], PACE4 could eventually be explored as an oncologic target in thyroid cancer. This evidence concerns the gene PCSK6 and thyroid cancer.